FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx
This article was originally published in Scrip
In giving its blessing to Eli Lilly & Co. on March 22 to market Taltz (ixekizumab) as a treatment for adults with moderate-to-severe plaque psoriasis, the FDA created a new rivalry for Novartis AG's medicine Cosentyx (secukinumab).
You may also be interested in...
Lilly's Taltz Approved For AS As New Guidelines Keep TNF Inhibitors In Front Line
VP Rebecca Morison said the ankylosing spondylitis indication adds more evidence of Taltz's benefits. She noted Lilly believes there should be fewer steps before AS patients access IL-17 inhibitors.
Novartis Champions Cosentyx With More Long-Term Psoriasis Data
Although its focus may be shifting somewhat towards other indications, the Swiss major has reported study read-outs that demonstrate the long-term efficacy of its IL-17A inhibitor blockbuster in nail and palmoplantar psoriasis.
Novartis Has Blockbuster Targets For Cosentyx In New Autoimmune Indications
Next up for Cosentyx is psoriatic arthritis and ankylosing spondylitis. Novartis presented impressive long-term efficacy data at ACR in PsA and AS. Incoming CEO and Chief Medical Officer Vas Narasimhan said the company sees a blockbuster opportunity and is exploring the anti-TNF naïve market in AS.